ERBB2 and breast cancer: Despite the fact that trastuzumab is considered the drug for excellence in HER2 positive metastatic [9,10], locally advanced and early BC [8], diagnostic approaches to assess the HER2 status are often vital and the need to solve many controversial issues in oncogene testing still pose a challenge [11,12].